CXCL13 is a plasma biomarker of germinal center activity

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel:	Proceedings of the National Academy of Sciences
Personen und Körperschaften:	Havenar-Daughton, Colin, Lindqvist, Madelene, Heit, Antje, Wu, Jennifer E., Reiss, Samantha M., Kendric, Kayla, Bélanger, Simon, Kasturi, Sudhir Pai, Landais, Elise, Akondy, Rama S., McGuire, Helen M., Bothwell, Marcella, Vagefi, Parsia A., Scully, Eileen, Tomaras, Georgia D., Davis, Mark M., Poignard, Pascal, Ahmed, Rafi, Walker, Bruce D., Pulendran, Bali, McElrath, M. Juliana, Kaufmann, Daniel E., Crotty, Shane, Price, Matt A., Gilmour, Jill, Fast, Pat, Kamali, Anatoli, Sanders, Eduard J., Onzala, Omu, Allen, Susan, Hunter, Eric, Karita, Etienne, Kilembe, William, Lakhi, Shabir, Inambao, Mubiana
In:	Proceedings of the National Academy of Sciences, 113, 2016, 10, S. 2702-2707
Format:	E-Article
Sprache:	Englisch
veröffentlicht:	Proceedings of the National Academy of Sciences
Schlagwörter:	Multidisciplinary

Details
Zusammenfassung:	<jats:title>Significance</jats:title> <jats:p>A major challenge for vaccine science is that there is no way to measure germinal center activity in humans. This challenge is particularly acute for human clinical trials of candidate vaccines (and most nonhuman primate studies of candidate vaccines), because germinal centers are the engines of Ab affinity maturation, and generation of highly affinity-matured Ab responses is the goal of all Ab-eliciting vaccines. Here, we report that we have identified the chemokine CXCL13 [chemokine (C-X-C motif) ligand 13] as a biomarker of germinal center activity. We show explicit relationships between plasma CXCL13 concentrations and germinal center frequencies in lymph nodes in a series of different conditions, including licensed and experimental vaccines, and in humans, nonhuman primates, and mice.</jats:p>
Umfang:	2702-2707
ISSN:	0027-8424 1091-6490
DOI:	10.1073/pnas.1520112113